“We are excited to partner with DWHP and are very thankful to Stout for introducing us to DWHP and initiating and driving the completion of this very complex and important transaction,” co-founder & CEO Pierre Rigaux said in a press release. “We believe that DWHP is the ideal partner for Cefaly as the company enters its next stage of fast growth and continues down the path of transforming the way migraines are treated globally.”
Liège, Belgium-based Cefaly developed neurostimulation medical devices to treat migraine headaches. The Cefaly device is non-invasive and can be self-administered to deliver electrical impulses to the trigeminal nerve.
Global advisory and consulting firm Stout led the acquisition transaction.
“Cefaly is at the forefront of non-invasive neuromodulation for the treatment of migraines with impressive results in the elimination and/or reduction of migraine pain,” managing director and head of Stout’s healthcare and life sciences industry practice John Calcagnini said. “We anticipate that growing numbers of patients worldwide will adopt their devices as stand-alone neuromodulation indications that they can pursue or out-license. Pierre and his team were a pleasure to work with, as was DW Healthcare Partners.”